Terms: = Colorectal cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
1778 results:
1. The Relationship of Microsatellite Instability with BRAF and p53 Mutations and Histopathological Parameters in colorectal Adenocarcinoma.
Gündoğar Ö; Bektaş S; Yıldırım E; Gönüllü D
Ann Ital Chir; 2024; 95(2):181-191. PubMed ID: 38684491
[TBL] [Abstract] [Full Text] [Related]
2. H
Qiao L; Ou Y; Li L; Wu S; Guo Y; Liu M; Yu D; Chen Q; Yuan J; Wei C; Ou C; Li H; Cheng D; Yu Z; Li Z
J Nanobiotechnology; 2024 Apr; 22(1):205. PubMed ID: 38658965
[TBL] [Abstract] [Full Text] [Related]
3. [Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract] [Full Text] [Related]
4. A cross-sectional study of sleep disturbance among middle-aged cancer patients at Vietnam National cancer Hospital.
Pham AT; Do MT; Tran HTT
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2055. PubMed ID: 38577715
[TBL] [Abstract] [Full Text] [Related]
5. Association between microsatellite status and characteristics and outcomes of early-onset compared to late-onset rectal cancer.
Emile SH; Horesh N; Garoufalia Z; Gefen R; Zhou P; Strassmann V; Wexner SD
Int J Colorectal Dis; 2024 Mar; 39(1):43. PubMed ID: 38538931
[TBL] [Abstract] [Full Text] [Related]
6. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
Moreau M; Alouani E; Flecchia C; Falcoz A; Gallois C; Auclin E; André T; Cohen R; Hollebecque A; Turpin A; Pernot S; Masson T; Di Fiore F; Dutherge M; Mazard T; Hautefeuille V; Van Laethem JL; De la Fouchardière C; Perkins G; Ben-Abdelghani M; Sclafani F; Aparicio T; Kim S; Vernerey D; Taieb J; Guimbaud R; Tougeron D
Eur J Cancer; 2024 May; 202():114033. PubMed ID: 38537314
[TBL] [Abstract] [Full Text] [Related]
7. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
[TBL] [Abstract] [Full Text] [Related]
8. Silver nanoparticles stimulate 5-Fluorouracil-induced colorectal cancer cells to kill through the upregulation TRPV1-mediated calcium signaling pathways.
Kaya MM
Cell Biol Int; 2024 May; 48(5):712-725. PubMed ID: 38499507
[TBL] [Abstract] [Full Text] [Related]
9. Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.
Benjamin DJ; Haslam A; Prasad V
Cancer Med; 2024 Mar; 13(5):e7049. PubMed ID: 38491813
[TBL] [Abstract] [Full Text] [Related]
10. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.
Lenz HJ; Parikh A; Spigel DR; Cohn AL; Yoshino T; Kochenderfer M; Elez E; Shao SH; Deming D; Holdridge R; Larson T; Chen E; Mahipal A; Ucar A; Cullen D; Baskin-Bey E; Kang T; Hammell AB; Yao J; Tabernero J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485190
[TBL] [Abstract] [Full Text] [Related]
11. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW
Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288
[TBL] [Abstract] [Full Text] [Related]
12. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Yan H; Song L; Li Y; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zhang Y; Zeng L
Cancer Immunol Immunother; 2024 Mar; 73(4):74. PubMed ID: 38451314
[TBL] [Abstract] [Full Text] [Related]
13. Complexity of surgery and treatment burden in patients with peritoneal malignancy is not determined by addition of hyperthermic intraperitoneal chemotherapy.
Steffens D; Ansari N; Koh C; Ahmadi N; Solomon MJ; Hogan S; Karunaratne S; Anderson T; Harvey K; McBride K; Moran B
ANZ J Surg; 2024 Apr; 94(4):628-633. PubMed ID: 38450829
[TBL] [Abstract] [Full Text] [Related]
14. Synergic actions of botulinum neurotoxin A and oxaliplatin on colorectal tumour cell death through the upregulation of TRPM2 channel-mediated oxidative stress.
Demir S; Duman İ; Nazıroğlu M
Clin Exp Pharmacol Physiol; 2024 Apr; 51(4):e13844. PubMed ID: 38350599
[TBL] [Abstract] [Full Text] [Related]
15. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract] [Full Text] [Related]
16. Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial.
Wu Z; Fu X; Jing H; Huang W; Li X; Xiao C; Li Z; You F
J Ethnopharmacol; 2024 May; 325():117853. PubMed ID: 38341113
[TBL] [Abstract] [Full Text] [Related]
17. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High colorectal cancer: A Preliminary Report of Case Series.
Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
[TBL] [Abstract] [Full Text] [Related]
18. Association of a novel frameshift variant and a known deleterious variant in MMR genes with Lynch syndrome in Chinese families.
Li J; Ni H; Wang X; Cheng W; Li L; Cheng Y; Liu C; Li Y; Deng A
World J Surg Oncol; 2024 Jan; 22(1):36. PubMed ID: 38280988
[TBL] [Abstract] [Full Text] [Related]
19. Salvage treatment of Recurrent or Persistent Anal Squamous Cell Carcinoma: The Role of Multi-modality Therapy.
Damron EP; McDonald J; Rooney MK; Das P; Ludmir EB; Minsky BD; Messick C; Chang GJ; Morris VK; Holliday EB
Clin Colorectal Cancer; 2024 Mar; 23(1):85-94. PubMed ID: 38216367
[TBL] [Abstract] [Full Text] [Related]
20. Patient-Reported Financial Burden of treatment for Colon or Rectal cancer.
Kircher S; Duan F; An N; Gareen IF; Sicks JD; Sadigh G; Suga JM; Kehn H; Mehan PT; Bajaj R; Hanson DS; Dalia SM; Acoba JD; Yasar DG; Park ER; Wagner LI; Carlos RC
JAMA Netw Open; 2024 Jan; 7(1):e2350844. PubMed ID: 38194233
[TBL] [Abstract] [Full Text] [Related]
[Next]
